Orchestra BioMed (OBIO) CEO buys 5,000 shares at $4.07
Orchestra BioMed Holdings (OBIO) insider trading report: A company director and officer, who serves as Chief Executive Officer and Chairperson, reported an open-market purchase of 5,000 shares of common stock on 11/14/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Orchestra BioMed Holdings (OBIO) insider trading report: A company director and officer, who serves as Chief Executive Officer and Chairperson, reported an open-market purchase of 5,000 shares of common stock on 11/14/2025. The shares were bought at a weighted average price of $4.07 per share, with individual trades executed between $4.06 and $4.10.
Following this transaction, the insider beneficially owns 612,822 shares directly. Additional indirect holdings are reported through several family trusts, including 442,765 shares held by the DPH 2008 Trust and smaller positions held by other named family trusts.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, par value $0.0001 per share ("Common Stock") | 5,000 | $4.07 | $20K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did OBIO report in this Form 4?
The filing reports that a director and officer of Orchestra BioMed Holdings, Inc. (OBIO) purchased 5,000 shares of common stock in an open-market transaction on 11/14/2025.
What indirect OBIO holdings are reported for the insider?
The insider reports indirect ownership including 442,765 shares held by the DPH 2008 Trust, and smaller amounts held by the Solomon Ascher Hochman 2019 Trust, Hannah Hochman 2019 Trust, Judah Herman Hochman 2019 Trust, and the NSH 2008 Family Trust.
What is the insider’s role at Orchestra BioMed Holdings (OBIO)?
The reporting person is identified as Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc.
Was the OBIO insider purchase executed in multiple trades?
Yes. The filing notes that the reported price is a weighted average and that the shares were purchased in multiple transactions within the $4.06 to $4.10 price range.
AI-generated analysis. How Rhea-AI works. Not financial advice.
